Longevity & AgingResearch PaperOpen Access

Blocking Two Immune Signals Shields Hearts From mRNA Vaccine Myocarditis in Mice

Preclinical work links CXCL10 and IFN-γ surges to mRNA vaccine heart injury; neutralizing them or giving genistein reduced damage in mice and human cell models.

Saturday, November 14, 2026 3 views
Published in Sci Transl Med
Glowing human heart cross-section with macrophages and T cells releasing chemokine molecules, a genistein molecule blocking the signal

Summary

Rare myocarditis after mRNA COVID-19 vaccination, mostly in young males after the second dose, has an unclear cause. Researchers combined published human plasma data, human stem cell-derived macrophages, T cells, cardiomyocytes and cardiac spheroids, and mouse models to look for mediators. They found that the chemokine CXCL10 (made mainly by macrophages) and IFN-γ (made mainly by T cells) rise early after vaccination and are higher in patients with myocarditis. Neutralizing both reduced cardiac injury markers and immune cell infiltration in vaccinated mice without greatly lowering antibody responses. Genistein, a plant-derived phytoestrogen, also reduced injury in cell and mouse models, apparently by dampening immunoproteasome activity. The findings are preclinical and do not yet support clinical use.

0:00--:--

Detailed Summary

Myocarditis after mRNA COVID-19 vaccination is rare but well documented, especially in males under 30 after the second dose, with symptoms about 1 to 3 days after injection. Most cases resolve, but the mechanism has been unclear. This matters for the safety of future mRNA vaccines and therapeutics, which are expected to expand into cancer, gene editing and other uses.

The authors first reanalyzed published human data: plasma cytokine time courses after BNT162b2 vaccination and a comparison of patients with vaccine-associated myocarditis against vaccinated controls. Among 27 shared cytokines, CXCL10 and IFN-γ peaked on days 1 to 2, were largest after dose two, and were higher in myocarditis patients. In human iPSC-derived macrophages, both Pfizer and Moderna vaccines induced CXCL10 in a dose-dependent way. Co-culture experiments suggested a two-phase model: macrophages make CXCL10 and recruit and activate T cells, and the T cells then produce most of the IFN-γ.

In BALB/c and C57BL/6 mice, two intramuscular BNT162b2 doses 21 days apart (2 μg) raised serum cardiac troponin I, with a peak 6 to 10 hours after the second dose, while ejection fraction stayed normal. Neutralizing CXCL10 and IFN-γ before dose two lowered troponin, IFN-γ-responsive gene expression, and neutrophil and macrophage infiltration in the heart. Anti-Spike IgG remained about 80% of vaccine-only levels. In iPSC-derived cardiac spheroids, conditioned medium from vaccine-stimulated immune cells raised NT-proBNP and impaired contractility, and inhibitors partly reversed this. Exposing iPSC-cardiomyocytes to the cytokines at concentrations estimated from human data impaired contractility, prolonged field potential duration, increased arrhythmia-like events, and induced inflammatory and immunoproteasome genes. IFN-γ was the main driver, with CXCL10 adding modestly.

Genistein protected iPSC-cardiomyocytes, reducing STAT1 signaling, NT-proBNP release, loss of structural proteins and immunoproteasome activity. It also reduced inflammatory activity in endothelial cells, macrophages and PBMCs. In mice, 7 days of oral genistein (50 mg/kg) before cytokine injection or the second vaccine dose lowered troponin, cytokine surges, and neutrophil and macrophage infiltration without reducing antibody titers.

Caveats: these are preclinical models. Mouse troponin rises do not equal human myocarditis, human data were reanalyzed from published studies, and the intervention timing is prophylactic. Genistein's efficacy and safety for this purpose in people are untested, so the work generates hypotheses rather than treatment guidance.

Key Findings

  • CXCL10 and IFN-γ peak 1–2 days after mRNA vaccination, are largest after dose two, and are higher in vaccine myocarditis patients.
  • Macrophages mainly produce CXCL10 while T cells supply most IFN-γ, suggesting a two-phase macrophage–T cell amplification loop.
  • Neutralizing CXCL10 and IFN-γ lowered troponin and cardiac neutrophil and macrophage infiltration in vaccinated mice, with ~80% of antibody titers retained.
  • The cytokines impaired contractility, prolonged field potential duration and raised arrhythmia-like events in iPSC-cardiomyocytes via immunoproteasome activation.
  • Oral genistein reduced cytokine surges, troponin and immune infiltration in vaccinated mice without lowering anti-Spike IgG.

Methodology

The study combined reanalysis of published human plasma and scRNA-seq datasets with human iPSC-derived macrophages, T cells, endothelial cells, cardiomyocytes and cardiac spheroids (RNA-seq, proteomics, contractility, MEA). Mouse experiments used BALB/c and C57BL/6 mice given two 2-μg BNT162b2 doses 21 days apart, with cytokine neutralization or oral genistein before dose two.

Study Limitations

All causal evidence comes from mice and in vitro iPSC systems, which cannot fully replicate human myocarditis, and mouse models showed troponin elevation without functional decline. Human mechanistic support relied on reanalyzed published datasets with small myocarditis cohorts, and genistein was tested only prophylactically at a single dose. The full discussion was truncated in the provided text, so some author-stated limitations may be missing.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: